Massachusetts is currently home to 3202 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Boston, Worcester, Springfield and Burlington. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Effect of Support for Low-Income Mothers of Preterm Infants
NCT06362798
Recruiting
Preterm birth is a leading cause of childhood mortality and developmental disabilities. Socioeconomic disparities in the incidence of preterm birth and morbidities, mortality, and quality of care for preterm infants persist. An important predictor of the long-term consequences of preterm birth is maternal presence during the prolonged infant hospitalization (weeks to months) in the neonatal intensive care unit (NICU). Mothers who visit the NICU can pump breast milk, directly breastfeed and engag... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/25/2025
Locations: Boston Medical Center, Boston, Massachusetts
Conditions: Preterm Birth, Low; Birthweight, Extremely (999 Grams or Less)
Register for Updates
A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis with Decitabine Combined with Filgrastim for Children and Young Adults with AML, MDS and Related Myeloid Malignancies
NCT05796570
Recruiting
The purpose of this study is to examine if it is feasible to administer decitabine and filgrastim after allogenic hematopoietic stem cell transplant (HCT) in children and young adults with myelodysplastic syndrome, acute myeloid leukemia and related myeloid disorders, and if the treatment is effective in preventing relapse after HCT. The names of the study drugs involved in this study are: * Decitabine (a nucleoside metabolic inhibitor) * Filgrastim (a recombinant granulocyte colony-stimulatin... Read More
Gender:
ALL
Ages:
Between 1 year and 39 years
Trial Updated:
03/25/2025
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myeloid Malignancies, MDS, Inherited Bone Marrow Failure Syndrome, Myeloid Neoplasm, Aml
Register for Updates
Percutaneous Intervention Versus Observational Trial of Arterial Ductus in Low Weight Infants
NCT05547165
Recruiting
Patent Ductus Arteriosus is a developmental condition commonly observed among preterm infants. It is a condition where the opening between the two major blood vessels leading from the heart fail to close after birth. In the womb, the opening (ductus arteriosus) is the normal part of the circulatory system of the baby, but is expected to close at full term birth. If the opening is tiny, the condition can be self-limiting. If not, medications/surgery are options for treatment. There are two ways... Read More
Gender:
ALL
Ages:
Between 7 days and 32 days
Trial Updated:
03/25/2025
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Ductus Arteriosus, Patent
Register for Updates
Physiological Assessment of Severe Coronary Stenosis for Informing Planned PCI
NCT05491668
Recruiting
Traditionally, the severity of a blockage (stenosis) in a coronary artery has been determined by visual angiographic assessment of the diameter of the artery at the level of a blockage compared to a normal healthy area of the same artery. With the advent of invasive physiological testing to assess coronary blood flow, multiple clinical trials have demonstrated a clinical benefit to a physiology-guided percutaneous coronary intervention (PCI) approach. However, despite this and the potential for... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/25/2025
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Coronary Artery Disease
Register for Updates
UPLYFT For Lymphoma Survivors
NCT05080166
Recruiting
The main purpose of this study is to field test and pilot an intervention called UPLYFT (Understand and Prevail: Lymphoma Fear of Recurrence Therapy) that includes information about lymphoma survivorship and tools to improve quality of life and reduce lymphoma-related worries among lymphoma survivors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/25/2025
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Lymphoma, Survivorship
Register for Updates
American Lung Association (ALA) Lung Health Cohort
NCT04543461
Recruiting
The ALA-LHC is a longitudinal, multi-center cohort study that will enroll approximately 4,000 young adults between the ages of 25-35 who do not have severe lung disease. The overarching objective of the ALA-LHC is to establish a national cohort of young adults for the purpose of defining lung health and developing targets to intercept chronic lung disease at its earliest stages.
Gender:
ALL
Ages:
Between 25 years and 35 years
Trial Updated:
03/25/2025
Locations: Brigham and Women's, Boston, Massachusetts
Conditions: Lung Diseases
Register for Updates
Phase 2 Trial of Voyager V1 in Combination with Cemiplimab in Cancer Patients
NCT04291105
Recruiting
This is a Phase 2 study designed to determine the preliminary anti-tumor activity and confirm the safety of VV1 in combination with cemiplimab. The study will enroll patients with three distinct separate tumor cohorts. The cancers types are colorectal, head and neck carcinoma, and melanoma that are progressing on CPI treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/25/2025
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Conditions: Melanoma, Head and Neck Squamous Cell Carcinoma, Colo-rectal Cancer
Register for Updates
ctDNA in Cutaneous Squamous Cell Carcinoma
NCT06875609
Recruiting
The purpose of this study is to test the potential for a liquid biopsy assay to detect residual disease after surgery in patients with cutaneous squamous cell carcinoma as well as the potential for this assay to monitor response to immunotherapy treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/24/2025
Locations: Massachusetts Eye and Ear, Boston, Massachusetts
Conditions: Cutaneous Squamous Cell Carcinoma
Register for Updates
Early Intervention in High Risk CCUS
NCT06802146
Recruiting
This research is being done to find out more about the potential risks and benefits of early treatment in participants with high risk Clonal Cytopenia of Unknown Significance (CCUS). This study will give eligible CCUS participants the option of either being observed or taking an oral drug as treatment. The names of the study drug involved in this study is: -Decitabine/cedazuridine (DEC/CED) (a nucleoside metabolic inhibitor and cytidine deaminase inhibitor).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/24/2025
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Clonal Cytopenia of Undetermined Significance, Cytopenia
Register for Updates
Advanced Imaging for Pulmonary Fibrosis
NCT06532071
Recruiting
The purpose of this study is to determine if measurements of active collagen deposition using \[68Ga\]CBP8 positron emission tomography (PET) and tissue injury using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) can predict an individual patient's pace of disease progression in non-idiopathic pulmonary fibrosis interstitial lung disease (non-IPF ILD) and identify which individuals will develop progressive pulmonary fibrosis.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
03/24/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Pulmonary Fibrosis
Register for Updates
A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators
NCT06504589
Recruiting
The REACH study is for people with CF who do not take cystic fibrosis transmembrane conductance regulator (CFTR) modulators. The goal of the REACH study is to collect research data, including health data and specimens, from people with CF who do not take CFTR modulators. This data may be used to inform CF research, help design CF clinical trials and support the development of new treatments for people with CF who do not take CFTR modulators. Another goal of this study is to learn about research... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
03/24/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Cystic Fibrosis
Register for Updates
Revumenib in Combination With 7+3 + Midostaurin in AML
NCT06313437
Recruiting
This research is being conducted to determine a safe and effective dose of revumenib that can be given in combination with standard induction (initial therapy to induce a remission) + FLT3 targeted therapy (midostaurin) and a single cycle of post-remission therapy + FLT3 targeted therapy (midostaurin) to participants with newly diagnosed Nucleophosmin (NPM1) and FMS-like tyrosine kinase 3 (FLT3) mutated Acute Myeloid Leukemia (AML). The names of the study drugs involved in this study are: * Re... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/24/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Acute Myeloid Leukemia, AML, Adult, AML With Gene Mutations, AML, Leukemia
Register for Updates